NSC 95397

目录号: HY-108543 纯度: ≥99.0%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

NSC 95397 是一种有效选择性的 Cdc25 双特异性磷酸酶抑制剂 (Cdc25A、Cdc25B 以及 Cdc25C 的 K_i 值分别为 32、96、40 nM，人亚型 Cdc25A、人亚型 Cdc25C 以及 Cdc25B 的 IC₅₀ 值分别为 22.3、56.9、125 nM)。NSC 95397 抑制丝裂原活化蛋白激酶磷酸酶-1 (MKP-1)，并通过 MKP-1 和 ERK1/2 途径抑制结肠癌细胞的增殖并诱导细胞凋亡。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

NSC 95397 Chemical Structure

CAS No. : 93718-83-3

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
1 mg	￥516	In-stock
5 mg	￥1200	In-stock
10 mg	￥1800	In-stock
25 mg	￥3550	In-stock
50 mg	￥5250	In-stock
100 mg	现货	询价
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

MCE 顾客使用本产品发表的 7 篇科研文献

NSC 95397 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
纯度 & 产品资料
参考文献

生物活性

NSC 95397 is a potent, selective Cdc25 dual specificity phosphatase inhibitor (K_i=32 nM (Cdc25A), 96 nM (Cdc25B), 40 nM (Cdc25C); IC₅₀=22.3 nM (human Cdc25A), 56.9 nM (human Cdc25C), 125 nM (Cdc25B))^[1]. NSC 95397 inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) and suppresses proliferation and induces apoptosis in colon cancer cells through MKP-1 and ERK1/2 pathway^[2].

IC₅₀ & Target

Ki: 32 nM (Cdc25A), 96 nM (Cdc25B), 40 nM (Cdc25C)^[1]
IC50: 22.3 nM (human Cdc25A) , 56.9 nM (human Cdc25C), 125 nM (Cdc25B)^[1]

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	1.45 μM Compound: NCS 95397	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28431339]
A549	IC₅₀	13.1 μM Compound: 4; NSC 95397	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
HeLa	IC₅₀	10.8 μM Compound: NSC-95397	Cytotoxicity against human HeLa cells after 6 days by WST1 colorimetric assay Cytotoxicity against human HeLa cells after 6 days by WST1 colorimetric assay	[PMID: 18789703]
HeLa	IC₅₀	8.5 μM Compound: NSC-95397	Antiproliferative activity against human HeLa cells after 10 days by clonogenic assay Antiproliferative activity against human HeLa cells after 10 days by clonogenic assay	[PMID: 18789703]
HL-60	IC₅₀	1 μM Compound: 4; NSC 95397	Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
Hs 683	IC₅₀	2.8 μM Compound: NCS 95397	Cytotoxicity against human Hs683 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human Hs683 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28431339]
Jurkat	IC₅₀	3.7 μM Compound: 4; NSC 95397	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
LS174T	IC₅₀	18.1 μM Compound: 4; NSC 95397	Cytotoxicity against human LS174T cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human LS174T cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
MCF7	IC₅₀	0.96 μM Compound: NCS 95397	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28431339]
MCF7	IC₅₀	9.4 μM Compound: 4; NSC 95397	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
MONO-MAC-6	IC₅₀	4.2 μM Compound: 4; NSC 95397	Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
PBMC	IC₅₀	7.8 μM Compound: 4; NSC 95397	Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
PC-3	IC₅₀	3.4 μM Compound: NCS 95397	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28431339]
SK-MEL-28	IC₅₀	2.3 μM Compound: NCS 95397	Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28431339]
SW982	IC₅₀	7.9 μM Compound: 4; NSC 95397	Cytotoxicity against human SW982 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human SW982 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
THP-1	IC₅₀	1.4 μM Compound: 4; NSC 95397	Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
U-937	IC₅₀	3.9 μM Compound: 4; NSC 95397	Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]

体外研究
(In Vitro)

NSC 95397 (0, 10, and 20 μM; 24 hour) 以浓度依赖性方式降低三种结肠癌细胞系 SW480、SW620 和 DLD-1 的细胞活力^[2]。
NSC 95397(10 μM; 24 h) 在所有三种结肠癌细胞系 SW480、SW620 和 DLD-1 细胞中上调 p21，同时下调 CDK4 和 CDK6^[2]。
NSC 95397 (10 μM；24 h) 降低 Ser795 和 Ser807/811 上视网膜母细胞瘤蛋白 (Rb) 的磷酸化^[2]。
NSC 95397 (20 μM；24 h) 显著增加裂解的 caspase-9、-3、-7 和 PARP 水平^[2]。
NSC 95397 (10 μM；6 h) 增强其下游 ERK1/2 在 Thr202/Tyr 204 处的磷酸化^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	Human colon cancer cell lines, SW480, SW620, and DLD-1
Concentration:	0, 10, and 20 µM
Incubation Time:	24 hours
Result:	The IC₅₀ values of NSC 95397 for the cell growth of SW480, SW620, and DLD-1 cells were 9.9, 14.1 and 18.6 μM, respectively.

Western Blot Analysis^[2]

Cell Line:	SW480, SW620, and DLD-1 cells
Concentration:	10 μM
Incubation Time:	24 hours
Result:	p21 was upregulated while CDK4 and CDK6 were downregulated. Rduced the phosphorylation of Rb on Ser795 and Ser807/811

分子量

310.39

Formula

C₁₄H₁₄O₄S₂

CAS 号

93718-83-3

性状

固体

颜色

Light yellow to orange

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

细胞实验：

DMSO 中的溶解度 : ≥ 100 mg/mL (322.18 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.2218 mL	16.1088 mL	32.2175 mL
5 mM	0.6444 mL	3.2218 mL	6.4435 mL
10 mM	0.3222 mL	1.6109 mL	3.2218 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 10 mg/mL (32.22 mM); 澄清溶液

此方案可获得 ≥ 10 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 100.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 10 mg/mL (32.22 mM); 澄清溶液

此方案可获得 ≥ 10 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 100.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: ≥99.0%

选择批次：

Data Sheet (640 KB) SDS (393 KB)

COA (264 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Lazo JS, et al. Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. Mol Pharmacol. 2002 Apr;61(4):720-8. [Content Brief]

[2]. Dubey NK, et al. NSC 95397 Suppresses Proliferation and Induces Apoptosis in Colon Cancer Cells through MKP-1 and the ERK1/2 Pathway. Int J Mol Sci. 2018 May 31;19(6). pii: E1625. [Content Brief]

NSC 95397 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.2218 mL	16.1088 mL	32.2175 mL	80.5438 mL
	5 mM	0.6444 mL	3.2218 mL	6.4435 mL	16.1088 mL
	10 mM	0.3222 mL	1.6109 mL	3.2218 mL	8.0544 mL
	15 mM	0.2148 mL	1.0739 mL	2.1478 mL	5.3696 mL
	20 mM	0.1611 mL	0.8054 mL	1.6109 mL	4.0272 mL
	25 mM	0.1289 mL	0.6444 mL	1.2887 mL	3.2218 mL
	30 mM	0.1074 mL	0.5370 mL	1.0739 mL	2.6848 mL
	40 mM	0.0805 mL	0.4027 mL	0.8054 mL	2.0136 mL
	50 mM	0.0644 mL	0.3222 mL	0.6444 mL	1.6109 mL
	60 mM	0.0537 mL	0.2685 mL	0.5370 mL	1.3424 mL
	80 mM	0.0403 mL	0.2014 mL	0.4027 mL	1.0068 mL
	100 mM	0.0322 mL	0.1611 mL	0.3222 mL	0.8054 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

NSC 9539793718-83-3NSC95397NSC-95397PhosphataseApoptosisInhibitorinhibitorinhibit

您最近查看的产品:

产品名称：

* 需求量：

* 客户姓名：

* Email：

* 电话：

* 公司或机构名称：

留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4

上海工商

沪公网安备31011502019417

沪(浦)应急管危经许[2021]201709(QFYS)

营业执照（三证合一）

NSC 95397

Customer Review

MCE 顾客使用本产品发表的 7 篇科研文献